Goldstein DA - Search Results

1

Cancer Drug Pricing and Reimbursement: Lessons for the United States From Around the World.

Goldstein DA, Sarfaty M. Goldstein DA, et al. Oncologist. 2016 Aug;21(8):907-9. doi: 10.1634/theoncologist.2016-0106. Epub 2016 Jul 6. Oncologist. 2016. PMID: 27384235 Free PMC article.

2

Considering Efficacy and Cost, Where Does Ramucirumab Fit in the Management of Metastatic Colorectal Cancer?

Goldstein DA, El-Rayes BF. Goldstein DA, et al. Oncologist. 2015 Sep;20(9):981-2. doi: 10.1634/theoncologist.2015-0028. Epub 2015 Aug 11. Oncologist. 2015. PMID: 26265225 Free PMC article.

3

Necitumumab in Metastatic Squamous Cell Lung Cancer: Establishing a Value-Based Cost.

Goldstein DA, Chen Q, Ayer T, Howard DH, Lipscomb J, Ramalingam SS, Khuri FR, Flowers CR. Goldstein DA, et al. JAMA Oncol. 2015 Dec;1(9):1293-300. doi: 10.1001/jamaoncol.2015.3316. JAMA Oncol. 2015. PMID: 26313558 Clinical Trial.

4

Perspectives in Oncology Drug Pricing-Reply.

Goldstein DA, Howard DH, Flowers CR. Goldstein DA, et al. JAMA Oncol. 2016 Mar;2(3):402-3. doi: 10.1001/jamaoncol.2015.4997. JAMA Oncol. 2016. PMID: 26967189 No abstract available.

5

Cost description of chemotherapy regimens for the treatment of metastatic pancreas cancer.

Goldstein DA, Krishna K, Flowers CR, El-Rayes BF, Bekaii-Saab T, Noonan AM. Goldstein DA, et al. Med Oncol. 2016 May;33(5):48. doi: 10.1007/s12032-016-0762-8. Epub 2016 Apr 11. Med Oncol. 2016. PMID: 27067436

6

Understanding the value of cancer drugs-the devil is in the detail.

Goldstein DA. Goldstein DA. Cancer. 2016 Aug 1;122(15):2292-5. doi: 10.1002/cncr.30044. Epub 2016 May 10. Cancer. 2016. PMID: 27163796 Free article. No abstract available.

7

Economics of ramucirumab for metastatic colorectal cancer.

Zeichner SB, Kohn CG, Goldstein DA. Zeichner SB, et al. Among authors: goldstein da. Expert Rev Pharmacoecon Outcomes Res. 2016 Dec;16(6):733-745. doi: 10.1080/14737167.2016.1259070. Expert Rev Pharmacoecon Outcomes Res. 2016. PMID: 27828732 Review.

8

Bevacizumab for Metastatic Colorectal Cancer: A Global Cost-Effectiveness Analysis.

Goldstein DA, Chen Q, Ayer T, Chan KKW, Virik K, Hammerman A, Brenner B, Flowers CR, Hall PS. Goldstein DA, et al. Oncologist. 2017 Jun;22(6):694-699. doi: 10.1634/theoncologist.2016-0455. Epub 2017 Jun 7. Oncologist. 2017. PMID: 28592621 Free PMC article.

9

Cost Effectiveness of Nivolumab in Advanced Renal Cell Carcinoma.

Sarfaty M, Leshno M, Gordon N, Moore A, Neiman V, Rosenbaum E, Goldstein DA. Sarfaty M, et al. Among authors: goldstein da. Eur Urol. 2018 Apr;73(4):628-634. doi: 10.1016/j.eururo.2017.07.041. Epub 2017 Aug 12. Eur Urol. 2018. PMID: 28807351

10

Trajectories of Injectable Cancer Drug Costs After Launch in the United States.

Gordon N, Stemmer SM, Greenberg D, Goldstein DA. Gordon N, et al. Among authors: goldstein da. J Clin Oncol. 2018 Feb 1;36(4):319-325. doi: 10.1200/JCO.2016.72.2124. Epub 2017 Oct 10. J Clin Oncol. 2018. PMID: 29016226

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

450 results

Search Page

Filters